Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc was a commercial-stage biopharmaceutical company focused on sleep medicine before its acquisition by Alkermes plc. Its company updates centered on LUMRYZ, an FDA-approved sodium oxybate extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Recurring developments included LUMRYZ commercialization, clinical and regulatory disclosures for the REVITALYZ trial in idiopathic hypersomnia, operating and financial results, material agreements, shareholder voting matters, governance items and capital-structure changes tied to its public-company status and completed acquisition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.